作者
Seyed-Mohammad Reza Hashemian, Rasoul Aliannejad, Morteza Zarrabi, Masoud Soleimani, Massoud Vosough, Seyedeh-Esmat Hosseini, Hamed Hossieni, Saeid Heidari Keshel, Zeinab Naderpour, Ensiyeh Hajizadeh-Saffar, Elham Shajareh, Hamidreza Jamaati, Mina Soufi-Zomorrod, Naghmeh Khavandgar, Hediyeh Alemi, Aliasghar Karimi, Neda Pak, Negin Hossieni Rouzbahani, Masoumeh Nouri, Majid Sorouri, Ladan Kashani, Hoda Madani, Nasser Aghdami, Mohammad Vasei, Hossein Baharvand
发表日期
2021/12
期刊
Stem cell research & therapy
卷号
12
页码范围
1-12
出版商
BioMed Central
简介
Background
Acute respiratory distress syndrome (ARDS) is a fatal complication of coronavirus disease 2019 (COVID-19). There are a few reports of allogeneic human mesenchymal stem cells (MSCs) as a potential treatment for ARDS. In this phase 1 clinical trial, we present the safety, feasibility, and tolerability of the multiple infusions of high dose MSCs, which originated from the placenta and umbilical cord, in critically ill COVID-19-induced ARDS patients.
Methods
A total of 11 patients diagnosed with COVID-19-induced ARDS who were admitted to the intensive care units (ICUs) of two hospitals enrolled in this study. The patients were critically ill with severe hypoxemia and required mechanical ventilation. The patients received three intravenous infusions (200 × 106 cells) every other day for a total of 600 × 106 human umbilical cord MSCs (UC …
学术搜索中的文章
SMR Hashemian, R Aliannejad, M Zarrabi… - Stem cell research & therapy, 2021